By PPN News Staff
The FDA granted Octagam (IV immune globulin [Human] 10%, Octapharma USA) orphan drug designation for its treatment of dermatomyositis, a rare acquired disorder characterized by chronic inflammatory and degenerative changes of the muscles and skin.